YahooOctober 22, 2026 at 4:17 PM NY5 Days Ago
AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial
Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
